Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of LB1148 for accelerating gastrointestinal recovery after elective bowel resection
CTR20230420Phase 3Completed
- Sponsor
- Leading BioSciences, Inc.
- Start
- Mar 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative ileus (POI) comparing LB1148 with Placebo (2 arms). Primary endpoint: GI-2. Started Mar 2023; status: completed.
02
Drugs
LB1148
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on CTR20230420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230420.